🌍 Society & Frontier risk-off · 1–3 years
A what‑if from the future

What if $300B loss-of-exclusivity wave hits big pharma through 2030?

A stacked 2025-30 patent cliff (~$300B of branded sales) across Merck, BMS, J&J and others compresses pharma earnings growth to near zero and de-rates the sector vs the S&P.

38%
our model probability
over 1–3 years
prediction markets — wisdom of the crowd
loading live odds…
Empirically anchored 38% · 90% range 6–69% · 18 analogues · measured class health 42% in 3 yr · 3% held back for the unknown
how we built this number — every step
Measured class rate — health ≈0.1843/yr → 42% in 3 yr42%
Analyst prior · editorial share 100% of the class55%
Pooled · weight 75%39%
Crowd — no liquid market
Reserve 3% · no extremizing (×1.0)39%
Published38%

The class rate is measured from our dated, sourced event library (decade-normalized Poisson — the full table is public at base_rates.json). The variant’s share within its class is the analyst’s editorial call, published so you can audit it. A wider range means thinner precedent. Full recipe: methodology · scored at Reality Check.

The butterfly cascade

How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.

Resolution timeline — how this probability is moving

Our model's odds (gold) over time vs the crowd's (Polymarket, blue), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. The gold path is an illustrative reconstruction anchored to today's estimate — real dated events, not a live re-estimate history.

loading the timeline…

What it would mean

If this plays out, it is a risk-off shock. A stacked 2025-30 patent cliff (~$300B of branded sales) across Merck, BMS, J&J and others compresses pharma earnings growth to near zero and de-rates the sector vs the S&P. The trigger decomposes into signed root‑shocks — Biotech breakthrough ▼ · Consumer spending ▼ · Risk appetite ▼ — which propagate through our causal graph to the markets below.

If it happens — the markets it would move

Biggest moves first. Projected moves are cascade-model priors; hist A–B% = what comparable past events actually did (measured abnormal returns), and model prior · unmeasured marks markets with no analogue backing yet. Tap any market for its price history.

MarketClassProjected move
1Solana SOLon Hyperliquid 📈 chartCrypto▼ -0.4%
hist -9.24–+3.77%
2MicroStrategy MSTRon Hyperliquid 📈 chartEquity▼ -0.4%
hist -6.84–+10.95%
3Nasdaq 100 NDXon Hyperliquid 📈 chartIndex▼ -0.4%
hist -0.43–+0.22%
4Hyperliquid (HYPE) HYPEon HyperliquidCrypto▼ -0.4%
model prior · unmeasured
5Ether ETHon Hyperliquid 📈 chartCrypto▼ -0.3%
hist -3.11–+1.98%
6Bitcoin BTCon Hyperliquid 📈 chartCrypto▼ -0.2%
hist -3.53–+5.53%
7S&P 500 SPXon Hyperliquid 📈 chartIndex▼ -0.2%
hist -0.27–-0.02%
8Volatility (VIX) VIXon Hyperliquid 📈 chartVol▲ +0.2%
hist -1.27–+2.3%
9Tech sector XLK 📈 chartEquity▼ -0.2%
hist -0.57–+0.67%

Probable recommendation

If the scenario above plays out, the probable cross‑asset positioning → a scenario‑conditional read, not personalized investment advice
Cash / hedgeRaise cash and hold the long hedges above; this scenario is net risk-off.
For a common-man portfolio: A typical stock-heavy portfolio is at risk. Consider trimming equities, raising cash, and a small cash hedge.
Also moves (not yet on Hyperliquid): Tech sector -0.2%

Historical precedent — what analogous events actually did

Across 18 analogous events (overlap‑weighted), as abnormal returns — market beta stripped, so it's the event's own effect, not the market backdrop. Shown at 20 days (persistent) and 5 days (immediate); ↺ fades = the two horizons disagree. Confidence = consistency × sample × significance.

Wegovy 2021-06 First mRNA COVID-19 vaccine authorized 2020-12 Casgevy — first CRISPR gene-editing medicine approved 2023-12 mRNA pioneers win the Nobel 2023-10 First genetically-modified pig-to-human heart transplant 2022-01 AlphaFold cracks the protein-folding problem 2020-11 He Jiankui announces CRISPR-edited babies 2018-11 Human Genome Project completed 2003-04 Nikkei 225 record single-day rebound 2024-08 Neuralink implants its first human brain-computer interface 2024-01 LK-99 room-temperature superconductor claim 2023-07 OpenAI releases GPT-4 2023-03 NIF achieves fusion ignition 2022-12 AlphaGo defeats Lee Sedol 2016-03 SpaceX lands an orbital rocket booster 2015-12 2008 global rice crisis: Thai benchmark tops $1,000/ton 2008-04 Soviet August coup attempt against Gorbachev 1991-08 Cuban Missile Crisis 1962-10
AssetHistory saysAbnormal (20d · 5d)HitnConfidencevs cascade
SOL SOLSHORT-8.6% · 5d -8.9%80%11 0.44✓ matches cascade
US dollar DXYSHORT-0.6% · 5d -0.5%70%17 0.32·
Bitcoin BTCLONG+5.8% · 5d -5.1% ↺ fades59%14 0.17⚠ differs
Gold XAULONG+0.6% · 5d -0.1% ↺ fades60%16 0.16·
MSTR MSTRLONG+11.4% · 5d -0.9% ↺ fades55%16 0.09⚠ differs
XLK XLKLONG+0.8% · 5d +0.0%55%16 0.08⚠ differs
ETH ETHSHORT-3.0% · 5d -7.7%55%12 0.07✓ matches cascade
NDX NDXLONG+0.4% · 5d -0.4% ↺ fades55%17 0.06⚠ differs
10y yield DGS10LONG+2bp · 5d +1bp52%17 0.03·
SPX SPXSHORT-0.1% · 5d +1.4% ↺ fades39%17 0.00✓ matches cascade
Volatility VIXLONG+2.2% · 5d -5.2% ↺ fades50%17 0.00✓ matches cascade
High-yield credit HYGLONG+0.0% · 5d -0.2% ↺ fades44%15 0.00·

Methodology. Probability and impact are anchored to history and scored against what actually happens — wins and losses, in public, at Reality Check. Crowd odds live from Polymarket & Kalshi. By Vikas Singh, Quantitative Strategist. Updated 2026-07-03.